Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 14Completed 13Withdrawn 2Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

pembrolizumab 85Cyclophosphamide 74Nivolumab 58fludarabine 49Specimen Handling 49Magnetic Resonance Spectroscopy 43Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 30atezolizumab 27Gemcitabine 27Paclitaxel 26Ipilimumab 26Cisplatin 24venetoclax 23Radiation 23Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Temozolomide 18Lenalidomide 18Bevacizumab 17palbociclib 15Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Folfox protocol × Clear all
NCT06838338 2026-01-08

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

Peking University Cancer Hospital & Institute

Phase 1 Active not recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡